‘Cannabis Use Disorder’ Pill Clinical Trial To Begin

Is smoking too much cannabis starting to take a toll on your life? Drugs in capsule form may soon be the answer, if drug developers get their way.

Clinical research network based in South Florida Seagull’s Ordeal announced that it will conduct a Phase 2B trial to investigate new drugs. AEF0117-202created by Iris Falma To treat cannabis use disorder (CUD), according to Oct. 5 press releaseThis is a randomized, double-blind, placebo-controlled, four-arm, parallel-group, prospective, multicenter study to determine the efficacy of drugs that respond to the same receptors as THC.

AEF0117-202, under a new pharmacological class of drugs called sCB1-SSi, is often defined as the inability to stop using cannabis, even if it causes health and social problems. is the first clinical candidate for the treatment of

How much is too much pot? In this study, the criteria for meeting CUD were defined as people consuming cannabis at least five times a week. group, and a second group is given a placebo.

3 servings—1.0, 0.3, and 0.1 mg—and placebo were given to study participants in capsules. “AEF0117 acts in the same part of the brain as THC (tetrahydrocannabinol), the active ingredient in marijuana, and may temporarily alter some of the effects of cannabis,” the researchers wrote in their abstract. In their press release, they explained why:

“Chronic marijuana use can significantly impact an individual’s social and professional life in many ways, from poor job and academic performance to mood disorders,” said Segal Trials. Chief Scientific Officer and Medical Officer, Rishi Kakar, M.D., Ph.D. “This Phase 2B study brings us closer to the potential to effectively treat people who want to quit cannabis addiction but don’t have the tools to do so.”

“Dependency” can mean many things, including severe physical withdrawal symptoms from drugs such as opiates and alcohol, and unhealthy psychological patterns. A summary of this study describes cannabis withdrawal symptoms, including irritability, mood and sleep disturbances, loss of appetite, cravings, restlessness, and sometimes physical discomfort.

according to Centers for Disease Control and Prevention, one study estimates that about 3 in 10 people who consume cannabis have CUD. Another study estimates that people who use cannabis have about a 10% chance of becoming addicted.

Researchers Blame Possible Rise in CUD

Increased dubbing and better and more potent concentrates have been identified as the cause of an increase in cannabis use disorders.

“The potency of cannabis products has increased significantly over the past two decades,” which may have contributed to the increase in cannabis-related adverse effects. , Aelis Farma’s drug could have a significant, positive impact on the millions of marijuana users seeking to end their addiction to cannabis.”

Segal’s team conducts trials at the Psychedelic and Cannabis Research Center. The center was specifically built using pharmaceutical and regulatory feedback to create a structured inpatient environment that ensures both patient safety and patient comfort.

Interestingly, the team has also worked on psychedelics.Seagull Trials too recently announced It was the first large randomized clinical trial in the United States investigating MM-120 (LSD D-tartrate) for the treatment of generalized anxiety disorder (GAD).

Segal has already successfully developed 54 FDA-approved drugs and devices. The company says its trials will focus on psychiatry, neurology, addiction, insomnia, infectious diseases, vaccine development, and women’s health.